Mark Duncan

Dr. Mark Duncan, Chief Scientific Officer, and CSO at Target Discovery have extensive experience in mass spectrometry, clinical diagnostics, and analytical chemistry. Dr. Duncan was a Postgraduate Scholar at the Garvan Institute of Medical Research, Sydney, Australia, and thereafter, a Fogerty Fellow, National Institute of Neurological Disorders & Stroke, National Institutes of Health (NIH), Bethesda, MD. He has held appointments as a Professor (Medicine) at Universities in Australia, the USA, and Saudi Arabia and has established and directed proteomics/MS centers at three international institutions. He has also held senior appointments in the industry and is a co-developer of Veristrat®, a blood-based diagnostic used in the management of patients with non-small cell lung cancer marketed by Biodesix, Inc., Boulder, Colorado. He has published over 150 publications and has 8 issued patents. Dr. Duncan is co-editor, Special Features, Journal of Mass Spectrometry, he is on the editorial board, Journal of Clinical Mass Spectrometry and he is a member of the Committee on Quantitative Measurement of Proteins & Peptides by MS (C64), Clinical & Laboratory Standards Institute.